Researchers found GM-CSF crucial for MS disease progression, neutralizing it could reverse inflammation. A clinical trial is set to launch this year to test GM-CSF neutralization in patients.
Researchers detect 18 examples of antihelium-4, a massive antimatter partner of helium, in data from over 1 billion collisions at RHIC. The discovery could provide crucial insights into the early universe's matter-antimatter balance and the search for bulk antimatter elsewhere.
Researchers have identified GM-CSF as a driving force behind autoimmune diseases like MS. Blocking its activity may lead to new treatments for the disease. Dr. Abdolmohamad Rostami and his team found that GM-CSF is responsible for disease manifestation in an experimental animal model.
The STAR experiment has produced 18 examples of the nucleus of antihelium-4, making it the heaviest antiparticle ever detected. The discovery sheds light on the universe's matter-antimatter imbalance and could lead to breakthroughs in searching for antimatter in space.
A study by Fred Hutchinson Cancer Center researchers reveals a signaling protein called Reelin helps brain cells navigate during development. This finding may hold clues to understanding how cancer cells migrate within the body.
Researchers unveil unprecedented detail on how transporter proteins modulate neurotransmitter transfer and recycling. The study reveals the molecular workings of transporter proteins, essential for signaling in neurons, and sheds light on how they respond to binding molecules.
A new immunological technique has shown that artificially induced malaria immunity can last for at least 2.5 years, significantly longer than naturally acquired immunity. The study found that immune volunteers who were re-infected with the same strain of malaria had a quicker and more effective response to infection.
Researchers at the Broad Institute have developed a method to measure how much messenger RNA is produced and degraded, revealing dynamic changes in RNA levels over time. The technique allows for high-resolution and comprehensive views of the RNA lifecycle, enabling scientists to investigate what happens when something goes wrong in cells.
Combination therapy of loperamide and minocycline may provide a safer method for treating devastating lung infections in people with cystic fibrosis. The approach could cut drug development time in half, offering new hope for those affected by this genetic disease.